Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07235384 | A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis | PHASE1 | RECRUITING | 84 | — | — | Dec 1, 2025 | Dec 28, 2027 | Dec 19, 2025 | 1 | New Zealand |
| Arm | Type | Description |
|---|---|---|
| ZL-1503: Participants will receive single ascending doses of ZL-1503 | EXPERIMENTAL | Part A: Single Ascending Dose (SAD) |
| ZL-1503: Participants will receive multiple ascending doses of ZL-1503 | EXPERIMENTAL | Part B: Multiple Ascending Dose (MAD) |
| Name | Type | Description |
|---|---|---|
| ZL-1503 | DRUG | Healthy volunteers will receive ZL-1503. |
| Placebo | DRUG | Healthy volunteers will receive placebo. |
Inclusion Criteria: * Part A: 1. Healthy male and female volunteers, 18-65 years of age 2. Body mass index (BMI) between ≥ 18.5 and \< 32.5 kg/m2 3. Negative pregnancy tests for women of childbearing potential. * Part B: 1. 18-65 years of age; 2. BMI between ≥18.5 and \<40.0 kg/m2 3. ...